Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

555

HTML

7902

Figures (1-1)

280

Tables (1-3)

378

Sum=9115

Nov 26, 2011 (publication date) through Dec 21, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Nov 26, 2011; 3(11): 351-358
Published online Nov 26, 2011. doi: 10.4330/wjc.v3.i11.351

Table 2 Factors associated with an increased risk of bleeding

Author
Age > 65-70 yr
Female gender
CYP2C9 and/or VKORC1 gene polymorphism
Higher intensity of anticoagulation (i.e., INR > 4.5)
Labile INR (i.e., TTR < 60%)
Early 90 d of anticoagulation
History of bleeding
Comorbidities (i.e., hypertension, malignancy, liver and/or renal and/or cardiac failure)
Comedications (i.e., antiplatelet agents, non-steroidal anti-inflammatory drugs)

INR: International normalized ratio; TTR: Time within the therapeutic range.

Citation: Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol 2011; 3(11): 351-358
URL: https://www.wjgnet.com/1949-8462/full/v3/i11/351.htm
DOI: https://dx.doi.org/10.4330/wjc.v3.i11.351